Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7470-7480

  Castellano, Giancarlo ^a   Malaponte, Grazia ^b   Mazzarino, Maria C ^b   Figini, Mariangela ^a   Marchese, Francesco ^b   Gangemi, Pietro ^c   Travali, Salvatore ^b   Stivala, Franca ^b   Canevari, Silvana ^a   Libra, Massimo ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; SIGNAL TRANSDUCTION; TUMOR GENE; ZYMOGRAPHY; DISEASE COURSE; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSTATE TUMOR;

AGED; DISEASE PROGRESSION; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OSTEOPONTIN; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 58149348622     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0870     Document Type: Article

References (46)

1. Linton KD, Hamdy FC. Early diagnosis and surgical management of prostate cancer. Cancer Treat Rev 2003;29:151-60.
2. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007;176:1853-8.
3. Parekh DJ, Ankerst DP, Baillargeon J, et al. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1966-72.
4. Bradford TJ, Tomlins SA, Wang X, Chinnaiyan AM. Molecular markers of prostate cancer. Urol Oncol 2006;24:538-51.
5. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006;16:79-87.
6. El-Tanani MK, Campbell FC, Kurisetty V, et al. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006;17:463-74.
7. Khodavirdi AC, Song Z, Yang S, et al. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 2006;66:883- 8.
8. Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006;118:2255-61.
9. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002;95:506-12.
10. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6.
11. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 2001;41:723-49.
12. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 2003;278:28593-606.
13. van Kempen LC, Coussens LM. MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002;2:251-2.
14. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochemie 2005;87:287-97.
15. Festuccia C, Bologna M, Vicentini C, et al. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer 1996;69:386-93.
16. Jain S, Chakraborty G, Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C α/c-Src/IκB kinase α/β-dependent prostate tumor progression and angiogenesis. Cancer Res 2006;66:6638-48.
17. Desai B, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007;6:18.
18. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IκBα kinase-dependent nuclear factor κB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2004;279:38921-35.
19. Castellano G, Reid JF, Alberti P, et al. New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies. Cancer Res 2006;66:10709-19.
20. Subramanian A, Tamayo P, Mootha VK, et al. GeneSet Enrichment Analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:17745-50.
21. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6.
22. Tamura K, Furihata M, Tsunoda T, et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007;67:5117-25.
23. Gleason DF. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr 1988;7:15-8.
24. Signorelli SS, Malaponte G, Libra M, et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med 2005;10:1-6.
25. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513-21.
26. Safina A, Ren MQ, Vandette E, Bakin AV. TAK1 is required for TGF-β1-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene 2007;27:1198-207.
27. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007;26:6361-71.
28. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 2003;63:8511-5.
29. Bramwell VH, Doig GS, Tuck AB, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006;12:3337-43.
30. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007;67:330-40.
31. Gohji K, Nomi M, Hara I, Arakawa S, Kamidono S. Influence of cytokines and growth factors on matrix metalloproteinase-2 production and invasion of human renal cancer. Urol Res 1998;26:33-7.
32. Morgia G, Falsaperla M, Malaponte G, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 2005;33:44-50.
33. Incorvaia L, Badalamenti G, Rini G, et al. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res 2007;27:1519-25.
34. Zheng DQ, Woodard AS, Tallini G, Languino LR. Substrate specificity of α(v)β(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem 2000;275:24565-74.
35. Hahn A, Rahnenfuhrer J, Talwar P, Lengauer T. Confirmation of human protein interaction data by human expression data. BMC Bioinformatics 2005;6:112.
36. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007;26:717-24.
37. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-97.
38. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006;6:99-106.
39. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res 2004;121:228-41.
40. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300.
41. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51.
42. True L, Coleman I, Hawley S, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 2006;103:10991-6.
43. Nanni S, Priolo C, Grasselli A, et al. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res 2006;4:79-92.
44. Best CJ, Gillespie JW, Yi Y, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005;11:6823-34.
45. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
46. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.